Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMITIL and Radiotherapy in Cisplatin-Ineligible Head and Neck Cancer (LIPORAD-2)
NCT07920289Phase 2Not yet recruiting
- Sponsor
- Assuta Ashdod Medical Center
- Start
- Oct 2026
- Primary completion
- May 2028
01
Overview
Phase 2, open-label, single-arm trial of imipramine in head and neck squamous cell carcinoma (HNSCC), sponsored by Assuta Ashdod Medical Center. Primary endpoints: Short and Intermediate-Term Safety at 2 years and Event-Free Survival at 2 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
imipramine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07920289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920289.